10.75p+0.79 (+7.93%)24 Dec 2024, 13:37
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Renalytix PLC Fundamentals

Company NameRenalytix PLCLast Updated2024-12-24
IndustryHealth Information ServicesSectorHealthcare
Shares in Issue333.638 mMarket Cap£35.87 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.31EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio1.7215Debt Equity Ratio0
Asset Equity Ratio-0.4235Cash Equity Ratio-0.0803
Quick Ratio0.1508Current Ratio0.24
Price To Book Value0ROCE0

Renalytix PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Renalytix PLC Company Financials

Assets2024202320222021
Tangible Assets$216,000.00$1.19 m$1.37 m$2.46 m
Intangible Assets000$18.02 m
Investments$698,000.00$1.46 m$2.75 m0
Total Fixed Assets$1.85 m$3.75 m$5.31 m$26.57 m
Stocks000$353,000.00
Debtors$722,000.00$776,000.00$976,000.00$594,000.00
Cash & Equivalents$4.68 m$24.68 m$41.33 m$74.45 m
Other Assets000$6.09 m
Total Assets$7.97 m$30.63 m$50.06 m$102.58 m
Liabilities2024202320222021
Creditors within 1 year$11.49 m$16.14 m$11.78 m$7.26 m
Creditors after 1 year$4.33 m$7.53 m$7.68 m$213,000.00
Other Liabilities0000
Total Liabilities$15.83 m$23.66 m$19.46 m$7.48 m
Net assets-$7.85 m$6.97 m$30.61 m$95.10 m
Equity2024202320222021
Called up share capital$478,000.00$286,000.00$228,000.00$233,000.00
Share Premium$204.89 m$186.46 m$164.01 m$76.46 m
Profit / Loss-$33.45 m-$45.60 m-$45.25 m-$35.79 m
Other Equity-$7.85 m$6.97 m$30.61 m$95.10 m
Preference & Minorities0000
Total Capital Employed00$30.61 m$95.10 m
Ratios2024202320222021
Debt Ratio0$0.52$0.20$0.00
Debt-to-Equity0$1.08$0.25$0.00
Assets / Equity-0.4235-0.4235-0.4235-0.4235
Cash / Equity-0.0803-0.0803-0.0803-0.0803
EPS-$0.28-$0.50-$0.60-$0.51
Cash Flow2024202320222021
Cash from operating activities-$30.11 m-$34.09 m-$45.92 m-$24.63 m
Cashflow before financing-$19.86 m-$17.70 m-$20.29 m$52.61 m
Increase in Cash-$20.00 m-$16.65 m-$23.80 m$51.87 m
Income2024202320222021
Turnover$2.29 m$3.40 m$2.97 m$1.49 m
Cost of sales$2.13 m$2.68 m$2.10 m$804,000.00
Gross Profit$156,000.00$720,000.00$874,000.00$687,000.00
Operating Profit-$29.61 m-$42.22 m-$53.18 m-$32.61 m
Pre-Tax profit-$33.45 m-$45.60 m-$45.25 m-$35.79 m

Renalytix PLC Company Background

SectorHealthcare
ActivitiesRenalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Latest Interim Date15 Feb 2024
Latest Fiscal Year End Date1 Oct 2024

Renalytix PLC Directors

AppointedNamePosition
2022-04-07Ms. Ann E. BermanIndependent Director
2023-11-22Mr. Howard B. Doran, Jr.Chief Business Officer
2024-06-13Mr. Joel R. JungInterim Chief Financial Office
2023-07-11Mr. Thomas H. MclainPresident
2023-10-24Mr. Timothy John ScannellIndependent Director
2024-10-31Mr. Daniel Joseph LevangieNon-Executive Director
2024-12-11Mr. Christopher Harwood Bernard MillsNon-Executive Director
2024-12-11Mr. Julian Huw Baines MBEExecutive Director,Chairman
2020-07-17Mr. Richard Anthony EvansNon-Executive Director
2024-12-11Mr. James Renwick McCulloughExecutive Director,Chief Executive Officer
2024-12-20Mr. Fergus FlemingExecutive Director,Chief Technical Officer
2021-07-01Dr. Barbara MurphyIndependent Director
2023-07-03Dr. Erik LiumDirector
2024-12-03Mr. O. James SterlingChief Financial Officer and Principal Accounting Officer
2023-12-08Dr. Chirag Rohit ParikhIndependent Director
2023-07-07Dr. Michael J. Donovan, M.D.,PhDChief Medical Officer
2024-12-03Ms. Catherine Havlik CosteNon-Executive Director
2024-12-02Mr. Robert Graham NaylorNon-Executive Director

Renalytix PLC Contact Details

Company NameRenalytix PLC
Address19 Stanwell Road, Avon House, Cardiff, CF64 2EZ
Telephone
Websitehttps://www.renalytix.com

Renalytix PLC Advisors